Purple biotech reports second quarter 2025 financial results

Platform validating preclinical data presented at eacr 2025 for captn-3 tri-specific t cell engager show synergistic activity of the platform's masked cd3, nkg2a, and tumor-associated antigen arms

PPBT Ratings Summary

PPBT Quant Ranking